Developer docs
API playgroundTry for free, no card

Search company profiles

FendX Technologies

Full company profile

uuid0002f1y

Namestring
FendX Technologies
Legal namestring
FendX Technologies Inc.
Websiteurl
fendxtech.com
Company typeenum
Public
Founded yearint
2020
Descriptiontext

FendX Technologies Inc. (CSE: FNDX; OTCQB: FDXTF; FSE: E8D0) is a Canadian pre-revenue nanotechnology company developing surface protection products designed to reduce the spread of pathogens on high-touch surfaces and medical devices. The company's portfolio centers on three core technologies: (1) an antimicrobial nanoparticle-based liquid surface coating applied via brush or roller, which has demonstrated 99% reduction in MRSA and P. aeruginosa in lab testing; (2) a lubricated Foley catheter coating developed under a Collaborative Research Agreement with McMaster University, with demonstrated 99% reduction of E. coli in initial testing; and (3) an AI-enabled mobile application that uses smartphone imaging combined with reagents for real-time microbial contamination detection on surfaces (US Provisional #63/835,582). The IP base is anchored by exclusive McMaster University nanotechnology licenses, three pending US provisional applications, one granted US patent (12,390,545 B2, open-cell foam), and a pending US/EU patent family for foam-based wound treatment.

FendX is led by President & CEO Dr. Carolyn Myers (MBA, PhD), whose prior leadership roles include Allergan PLC, Mylan Technologies, Dey Laboratories, and Pharmacia, with CFO Rose Zanic (CPA, CA) providing capital markets and Canadian public-company administration experience. The company employs 1-10 people, has its registered office in Vancouver, BC, and operates as a publicly traded entity on the Canadian Securities Exchange (with cross-listings on OTCQB and Frankfurt).

The business model is pre-commercial: the company is not yet generating revenue and is pursuing commercialization through partnership and licensing pathways. Distribution is intended to be OEM/embedded (coatings licensed to or embedded in third-party products) and enterprise-focused across two customer segments. The primary segment is healthcare settings, including hospitals, healthcare facilities, and Foley catheter applications where the goal is to reduce healthcare-associated infections. The secondary segment is consumer and commercial markets, including transportation (airplanes, trains, buses), entertainment venues (arenas, theaters, casinos), hospitality, schools, and office buildings. The GTM motion is enterprise field sales, with commercialization advancing through an FDA regulatory pathway assessment (Innovotech Labs, April 2026) and pilot-scale manufacturing (Galenvs Sciences, April 2026). The company recently executed a strategic pruning, terminating the REPELWRAP film program (March 2026) and the Aquaox LLC collaboration (April 2026) to focus resources on the liquid coating, catheter coating, and AI detection app.

Short descriptiontext

FendX Technologies is a Canadian pre-revenue nanotechnology company developing antimicrobial liquid surface coatings, a Foley catheter coating, and an AI-enabled mobile pathogen-detection app to reduce pathogen spread on high-touch surfaces for healthcare and consumer/commercial markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersOakville, Canada
HQ citystring
Oakville
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antimicrobial surface coatings, nanotechnology surface protection, medical device coatings, AI pathogen detection, infection control products
Industry1 code
PRIMARYCRAJANAI
Natural/Plant-Based Surface Disinfectants
NAICS code2 codes
  • Research and Development in Nanotechnology541713
  • Surgical Appliance and Supplies Manufacturing339113
SIC code1 code
  • Specialty Cleaning, Polishing And Sanitation Preparations2842
Product category
Antimicrobial Surface Protection
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Product Sales (Future)
TypeOne Time License
Description

The company is pre-revenue and has not yet commercialized products. Revenue is expected from sale of surface coatings, Foley catheter coatings, and AI-powered detection applications.

newsfilecorp.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1REPELWRAP
Description

Film coating technology for surface protection (discontinued development as of March 2026)

fendxtech.com
+3 more records
Core offering1 text field

FendX Technologies develops and intends to commercialize nanotechnology-based surface protection products that reduce the spread of pathogens on high-touch surfaces and medical devices. Its core offerings are an antimicrobial liquid surface coating, a lubricated Foley catheter coating, and an AI-powered mobile app for real-time microbial contamination detection. Products are pre-commercial and in development, with pilot-scale manufacturing underway.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 99% reduction in MRSA and P. aeruginosa with liquid surface coating
+3 more records
Product overview1 text field

FendX Technologies is developing a portfolio of surface protection products to reduce the spread of pathogens. The product portfolio consists of three main offerings: (1) the Antimicrobial Liquid Surface Coating, a scalable nanoparticle-based coating applied via brush/roller for long-lasting antimicrobial protection on high-touch surfaces; (2) the Foley Catheter Coating, a specialized lubricated coating for medical catheters designed to inhibit bacterial growth; and (3) the AI-Driven Surface Contamination Detection App, a mobile application using AI and smartphone imaging to detect pathogens on surfaces in real-time. These products are designed to complement each other as integrated solutions—a layered protection approach combining physical coatings with digital monitoring capabilities. The company previously developed REPELWRAP film technology but discontinued it in March 2026 to focus on the liquid coating.

Product and service3 records
1Antimicrobial Liquid Surface Coating
CategoryAntimicrobial Surface Coatings
Description

A scalable nanoparticle-based liquid coating designed for easy application on high-touch surfaces via brush or roller, providing durable, long-lasting antimicrobial protection with demonstrated 99% reduction in MRSA and P. aeruginosa. Targeted at hospitals, transportation, hospitality, education, entertainment, and other high-touch environments.

2Foley Catheter Coating
CategoryMedical Device Coatings
Description

A specialized lubricated antimicrobial coating for Foley catheters designed to inhibit bacterial growth, demonstrating 99% reduction of E. coli in initial testing with strong durability characteristics. Developed under collaboration with McMaster University and intended for medical device manufacturers and healthcare providers.

3AI-Driven Surface Contamination Detection App
CategoryAI Pathogen Detection Software
Description

An AI-enabled mobile application designed to detect microbial contamination on surfaces in real-time using smartphone imaging and reagents. Complements FendX's physical coating technologies by enabling real-time monitoring and data-driven hygiene solutions for facility managers and infection-prevention teams.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierMajorTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-04-28
Description

Engaged to conduct regulatory research to determine the appropriate FDA classification and regulatory pathway for FendX's coated Foley catheter product. The scope includes assessment of regulatory requirements outlining the recommended FDA regulatory pathway. Following pathway determination, the company may engage Innovotech for antimicrobial testing services to support further development efforts.

2Galenvs Sciences Inc.
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-04-14
Description

Canadian contract manufacturing organization engaged to initiate pilot-scale manufacturing of FendX's liquid surface coating. The statement of work focuses on establishing scalable manufacturing processes with production of three independent lots to evaluate consistency and antimicrobial performance. This represents a key step toward commercialization of the surface coating technology.

stocktitan.net
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-27
Description

Ongoing collaboration under a Collaborative Research Agreement (CRA) for Foley catheter coating development. The company also has exclusive licenses for nanotechnology IP from McMaster. An amendment was signed on March 27, 2026 (effective November 30, 2025) to extend the catheter CRA term to May 31, 2026 and reduce payment commitments. The company terminated license agreements related to REPELWRAP film and original liquid coating formulation while maintaining excellent collaborative relations for future initiatives.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-11-17
Description

MOU signed November 17, 2025 to develop advanced formulations of eco-friendly pathogen-eliminating agents using Aquaox's hypochlorous acid (HOCl) technologies. A collaboration agreement was entered January 20, 2026 to assess technical feasibility. However, both the Collaboration Agreement (dated January 20, 2026) and MOU (dated November 17, 2025) were terminated in April 2026 as the initial technical feasibility phase was deemed not feasible. The company has since shifted focus to its existing surface protection solutions.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2025-03-11
Description

Provides investor relations, marketing and distribution services including social media (Reddit, Discord, Telegram, X/Twitter, StockTwits), digital and influencer-based marketing, content creation and distribution. The agreement was renewed and extended to June 30, 2026 with a fee reduction of $28,080 (inclusive of taxes). The company and OTB are arm's length.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

FendX Technologies

Antimicrobial Surface Protectionfendxtech.com

FendX Technologies is a Canadian pre-revenue nanotechnology company developing antimicrobial liquid surface coatings, a Foley catheter coating, and an AI-enabled mobile pathogen-detection app to reduce pathogen spread on high-touch surfaces for healthcare and consumer/commercial markets.

What FendX Technologies does

FendX Technologies Inc. (CSE: FNDX; OTCQB: FDXTF; FSE: E8D0) is a Canadian pre-revenue nanotechnology company developing surface protection products designed to reduce the spread of pathogens on high-touch surfaces and medical devices. The company's portfolio centers on three core technologies: (1) an antimicrobial nanoparticle-based liquid surface coating applied via brush or roller, which has demonstrated 99% reduction in MRSA and P. aeruginosa in lab testing; (2) a lubricated Foley catheter coating developed under a Collaborative Research Agreement with McMaster University, with demonstrated 99% reduction of E. coli in initial testing; and (3) an AI-enabled mobile application that uses smartphone imaging combined with reagents for real-time microbial contamination detection on surfaces (US Provisional #63/835,582). The IP base is anchored by exclusive McMaster University nanotechnology licenses, three pending US provisional applications, one granted US patent (12,390,545 B2, open-cell foam), and a pending US/EU patent family for foam-based wound treatment.

FendX is led by President & CEO Dr. Carolyn Myers (MBA, PhD), whose prior leadership roles include Allergan PLC, Mylan Technologies, Dey Laboratories, and Pharmacia, with CFO Rose Zanic (CPA, CA) providing capital markets and Canadian public-company administration experience. The company employs 1-10 people, has its registered office in Vancouver, BC, and operates as a publicly traded entity on the Canadian Securities Exchange (with cross-listings on OTCQB and Frankfurt).

The business model is pre-commercial: the company is not yet generating revenue and is pursuing commercialization through partnership and licensing pathways. Distribution is intended to be OEM/embedded (coatings licensed to or embedded in third-party products) and enterprise-focused across two customer segments. The primary segment is healthcare settings, including hospitals, healthcare facilities, and Foley catheter applications where the goal is to reduce healthcare-associated infections. The secondary segment is consumer and commercial markets, including transportation (airplanes, trains, buses), entertainment venues (arenas, theaters, casinos), hospitality, schools, and office buildings. The GTM motion is enterprise field sales, with commercialization advancing through an FDA regulatory pathway assessment (Innovotech Labs, April 2026) and pilot-scale manufacturing (Galenvs Sciences, April 2026). The company recently executed a strategic pruning, terminating the REPELWRAP film program (March 2026) and the Aquaox LLC collaboration (April 2026) to focus resources on the liquid coating, catheter coating, and AI detection app.

FendX Technologies firmographics

Firmographics
Name
FendX Technologies
Legal name
FendX Technologies Inc.
Website
https://fendxtech.com
Company type
Public
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
FendX Technologies is a Canadian pre-revenue nanotechnology company developing antimicrobial liquid surface coatings, a Foley catheter coating, and an AI-enabled mobile pathogen-detection app to reduce pathogen spread on high-touch surfaces for healthcare and consumer/commercial markets.
Ownership category
akta.pro rank

FendX Technologies industry classification

Industry
Product category
Antimicrobial Surface Protection
NAICS
Research and Development in Nanotechnology (541713), Surgical Appliance and Supplies Manufacturing (339113)
SIC
Specialty Cleaning, Polishing And Sanitation Preparations (2842)
akta.pro industry
PRIMARYCRAJANAI
Natural/Plant-Based Surface Disinfectants

Keywords

  • Antimicrobial surface coatings
  • Nanotechnology surface protection
  • Medical device coatings
  • AI pathogen detection
  • Infection control products

Where FendX Technologies is headquartered

Location

Headquarters

HQ city
Oakville
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

FendX Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

  1. Product Sales (Future): The company is pre-revenue and has not yet commercialized products. Revenue is expected from sale of surface coatings, Foley catheter coatings, and AI-powered detection applications.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

FendX Technologies product offering

Product offering

Core offering

FendX Technologies develops and intends to commercialize nanotechnology-based surface protection products that reduce the spread of pathogens on high-touch surfaces and medical devices. Its core offerings are an antimicrobial liquid surface coating, a lubricated Foley catheter coating, and an AI-powered mobile app for real-time microbial contamination detection. Products are pre-commercial and in development, with pilot-scale manufacturing underway.

Product overview

FendX Technologies is developing a portfolio of surface protection products to reduce the spread of pathogens. The product portfolio consists of three main offerings: (1) the Antimicrobial Liquid Surface Coating, a scalable nanoparticle-based coating applied via brush/roller for long-lasting antimicrobial protection on high-touch surfaces; (2) the Foley Catheter Coating, a specialized lubricated coating for medical catheters designed to inhibit bacterial growth; and (3) the AI-Driven Surface Contamination Detection App, a mobile application using AI and smartphone imaging to detect pathogens on surfaces in real-time. These products are designed to complement each other as integrated solutions—a layered protection approach combining physical coatings with digital monitoring capabilities. The company previously developed REPELWRAP film technology but discontinued it in March 2026 to focus on the liquid coating.

Differentiator

Problem solved

Functional benefit

Brands

  • REPELWRAP: Film coating technology for surface protection (discontinued development as of March 2026)
  • Antimicrobial Liquid Surface Coating
  • Foley Catheter Coating
  • AI-Powered Pathogen Detection App

Products and services

  • Antimicrobial Liquid Surface Coating A scalable nanoparticle-based liquid coating designed for easy application on high-touch surfaces via brush or roller, providing durable, long-lasting antimicrobial protection with demonstrated 99% reduction in MRSA and P. aeruginosa. Targeted at hospitals, transportation, hospitality, education, entertainment, and other high-touch environments.
  • Foley Catheter Coating A specialized lubricated antimicrobial coating for Foley catheters designed to inhibit bacterial growth, demonstrating 99% reduction of E. coli in initial testing with strong durability characteristics. Developed under collaboration with McMaster University and intended for medical device manufacturers and healthcare providers.
  • AI-Driven Surface Contamination Detection App An AI-enabled mobile application designed to detect microbial contamination on surfaces in real-time using smartphone imaging and reagents. Complements FendX's physical coating technologies by enabling real-time monitoring and data-driven hygiene solutions for facility managers and infection-prevention teams.

Quantifiable outcome

  • 99% reduction in MRSA and P. aeruginosa with liquid surface coating
  • +3 more outcomes

Companies that use FendX Technologies

Customer profile

Segments2 records

Ideal customer profiles2 records

FendX Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

FendX Technologies partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered major, core and minor.

  • Innovotech Labs CorporationmajorImplementation/ SI/ Consulting Partner · 28 April 2026Engaged to conduct regulatory research to determine the appropriate FDA classification and regulatory pathway for FendX's coated Foley catheter product. The scope includes assessment of regulatory requirements outlining the recommended FDA regulatory pathway. Following pathway determination, the company may engage Innovotech for antimicrobial testing services to support further development efforts.
  • Galenvs Sciences Inc.coreTechnology or Integration · 14 April 2026Canadian contract manufacturing organization engaged to initiate pilot-scale manufacturing of FendX's liquid surface coating. The statement of work focuses on establishing scalable manufacturing processes with production of three independent lots to evaluate consistency and antimicrobial performance. This represents a key step toward commercialization of the surface coating technology.
  • McMaster UniversitycoreStrategic or Co-development Partner · 27 March 2026Ongoing collaboration under a Collaborative Research Agreement (CRA) for Foley catheter coating development. The company also has exclusive licenses for nanotechnology IP from McMaster. An amendment was signed on March 27, 2026 (effective November 30, 2025) to extend the catheter CRA term to May 31, 2026 and reduce payment commitments. The company terminated license agreements related to REPELWRAP film and original liquid coating formulation while maintaining excellent collaborative relations for future initiatives.
  • Aquaox LLCminorStrategic or Co-development Partner · 17 November 2025MOU signed November 17, 2025 to develop advanced formulations of eco-friendly pathogen-eliminating agents using Aquaox's hypochlorous acid (HOCl) technologies. A collaboration agreement was entered January 20, 2026 to assess technical feasibility. However, both the Collaboration Agreement (dated January 20, 2026) and MOU (dated November 17, 2025) were terminated in April 2026 as the initial technical feasibility phase was deemed not feasible. The company has since shifted focus to its existing surface protection solutions.
  • Outside The Box Capital Inc.minorGTM or Marketing Partner · 11 March 2025Provides investor relations, marketing and distribution services including social media (Reddit, Discord, Telegram, X/Twitter, StockTwits), digital and influencer-based marketing, content creation and distribution. The agreement was renewed and extended to June 30, 2026 with a fee reduction of $28,080 (inclusive of taxes). The company and OTB are arm's length.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

FendX Technologies competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

FendX Technologies social profiles

Digital presence

FendX Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

FendX Technologies leadership team

Management profile

Number of profiles

Profiles5 records

FendX Technologies funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

FendX Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FendX Technologies

What does FendX Technologies do?

FendX Technologies develops and intends to commercialize nanotechnology-based surface protection products that reduce the spread of pathogens on high-touch surfaces and medical devices. Its core offerings are an antimicrobial liquid surface coating, a lubricated Foley catheter coating, and an AI-powered mobile app for real-time microbial contamination detection. Products are pre-commercial and in development, with pilot-scale manufacturing underway.

Is FendX Technologies a public or private company?

FendX Technologies is a public company. It is classified as public and is currently operating.

When was FendX Technologies founded?

FendX Technologies was founded in 2020. It employs 1 to 10 people.

Where is FendX Technologies based?

FendX Technologies is headquartered in Oakville, Canada, in the North America region.

How does FendX Technologies make money?

One revenue line is on record: product Sales (Future).

Does FendX Technologies have an API?

No public API is recorded for FendX Technologies.

What industry is FendX Technologies in?

FendX Technologies's product category is Antimicrobial Surface Protection. Its primary akta.pro industry code is CRAJANAI, Natural/Plant-Based Surface Disinfectants. Its NAICS code is 541713 and its SIC code is 2842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NewsfileFendX Announces Proposed Name ChangeFendX Technologies Inc. announced it will change its name to Marlin Health Inc. and its Canadian Securities Exchange symbol to MRLH, effective November 16, 2026. The change requires no shareholder action, and the company will pursue a corresponding OTC Markets symbol change.AktienFendX Announces Proposed Name ChangeFendX Technologies Inc. announced it will change its name to Marlin Health Inc. and its Canadian Securities Exchange symbol to MRLH, effective November 16, 2026. The change requires no shareholder action, and the company will update its OTC Markets and Frankfurt Stock Exchange symbols accordingly.Stock TitanFendX taps Innovotech for Foley catheter FDA pathwayFendX Technologies Inc. has engaged Innovotech Labs Corporation to conduct regulatory research and determine the appropriate FDA classification and regulatory pathway for its coated Foley catheter product currently in development. The agreement, dated April 28, 2026, is intended to establish a clear regulatory strategy as the company advances toward commercialization of the technology designed to reduce bacterial growth and infection risk associated with Foley catheter use. Following determination of the regulatory pathway, the next step will involve conducting antimicrobial testing, with potential engagement of Innovotech for those services.NewsfileFendX Engages Innovotech for Regulatory Pathway Assessment of Its Coated Foley Catheter ProgramFendX Technologies entered an agreement with Innovotech Labs to assess the FDA regulatory pathway for its coated Foley catheter. The scope includes determining the appropriate FDA classification and regulatory requirements. Following this, FendX plans antimicrobial testing, potentially using Innovotech's advanced methodologies.Stock TitanFendX starts pilot manufacturing for liquid coatingFendX Technologies Inc. has engaged Galenvs Sciences Inc., a Canadian contract manufacturing organization, to initiate pilot-scale manufacturing of its liquid surface coating, representing a key step toward commercialization. The coating has demonstrated effectiveness against MRSA and P. aeruginosa, and the project will produce three independent lots to evaluate scalability, quality consistency, and antimicrobial performance. The company also announced the termination of collaboration agreements with Aquaox LLC after the initial technical feasibility phase was deemed not feasible.NewsfileFendX Engages Galenvs for Pilot Scale-Up Manufacturing of Its Liquid Surface CoatingFendX Technologies signed a statement of work with Galenvs Sciences to initiate pilot-scale manufacturing of its liquid surface coating. The project will produce three independent lots for evaluation of consistency and antimicrobial performance. The coating has demonstrated activity against MRSA and P. aeruginosa, and a provisional patent was filed in October 2025.Stock TitanFendX shifts to liquid coating, drops REPELWRAPFendX Technologies Inc. announced on March 31, 2026 that it is prioritizing a newly developed liquid surface coating over its REPELWRAP film product, having demonstrated strong effectiveness against MRSA and P. aeruginosa in collaboration with McMaster University. The company simultaneously terminated license agreements for REPELWRAP and the original liquid coating formulation, effective February 1–2, 2026, while amending its Foley catheter coating research agreement to extend through May 31, 2026 with reduced payment commitments. FendX also disclosed a share-for-debt settlement of 242,102 common shares at $0.37 per share to settle $89,578 in consulting fees, and outlined plans to advance its liquid coating toward manufacturing scale-up.NewsfileFendX Provides Corporate UpdateFendX Technologies Inc. announced it has terminated license agreements with McMaster University for both the REPELWRAP film and original liquid coating formulations as of late February 2026, consolidating its development efforts around a new liquid surface coating that demonstrated effectiveness against MRSA and P. aeruginosa. The company also advanced its Foley catheter coating under a collaborative research agreement, filed provisional patents for the liquid coating, catheter coating, and an AI-driven microbial contamination detection app, and entered into a collaboration with Aquaox LLC to explore eco-friendly antimicrobial agents. Additionally, FendX completed share consolidation and debt settlement transactions while renewing its investor relations agreement with Outside The Box Capital Inc. through June 2026.NewsfileFendX Provides Corporate UpdateFendX Technologies Inc. has completed a previously disclosed debt settlement by issuing 34,540 common shares at $0.74 per share to settle $25,560 of debt with arms-length creditors. The company is carrying out this settlement to reduce existing liabilities and improve its financial position. The securities issued are subject to a hold period expiring four months and one day from the date of issuance in accordance with applicable securities laws.